Leap Therapeutics Inc LPTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/14/24 EDT
2.75UNCH (UNCH)
Volume
246,179
52 week range
1.24 - 10.20
Loading...
  • Open2.86
  • Day High3.00
  • Day Low2.72
  • Prev Close2.75
  • 52 Week High10.20
  • 52 Week High Date06/01/23
  • 52 Week Low1.24
  • 52 Week Low Date10/02/23

Key Stats

  • Market Cap105.227M
  • Shares Out38.26M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.46
  • YTD % Change-33.66

KEY STATS

  • Open2.86
  • Day High3.00
  • Day Low2.72
  • Prev Close2.75
  • 52 Week High10.20
  • 52 Week High Date06/01/23
  • 52 Week Low1.24
  • 52 Week Low Date10/02/23
  • Market Cap105.227M
  • Shares Out38.26M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.46
  • YTD % Change-33.66

RATIOS/PROFITABILITY

  • EPS (TTM)-2.39
  • P/E (TTM)-1.15
  • Fwd P/E (NTM)-1.19
  • EBITDA (TTM)-59.124M
  • ROE (TTM)-141.00%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-14,208.53%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Leap Therapeutics Inc

 

Profile

MORE
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized...
Christopher Mirabelli Ph.D.
Chairman of the Board
Douglas Onsi
President, Chief Executive Officer, Director
Augustine Lawlor
Chief Operating Officer
Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Address
47 Thorndike St Ste B1-1
Cambridge, MA
02141-1799
United States